Literature DB >> 26416040

Alternated intra-arterial and intravitreal chemotherapy for advanced intraocular retinoblastoma: preliminary successful results without systemic chemotherapy.

Sonia De Francesco1, Paolo Galluzzi2, Sandra Bracco2, Felice Menicacci3, Edoardo Motolese3, Theodora Hadjistilianou4.   

Abstract

To describe the efficacy of intravitreal chemotherapy (IViC) preceded by intra-arterial chemotherapy (IAC) for the treatment of advanced stage retinoblastoma. This non-comparative interventional case series retrospectively reviewed the medical records of six patients who presented within months of each other with unilateral retinoblastoma, Reese-Ellsworth stage Vb/D of ABC classification in the affected eye. After clinical and ophthalmoscopic evaluation, they underwent MRI to exclude local and CNS dissemination. The IAC was given to treat retinal masses and intravitreal injections to treat vitreous seeding. Patients had received two cycles (six infusions) of IAC, and from six up to ten melphalan injections into the vitreous, with an interval of 7-10 days between them. From one to four intravitreal injections were performed for partial remission or consolidation. No permanent complications of procedures have been reported. All patients underwent to bimonthly MRI examination, during treatment and every 3 months for 1 year after last injection, to exclude orbital dissemination. Successful control (100 %) of tumor masses and vitreous seeds was achieved in all cases at 12 months follow-up. Complications were posterior lens opacity, acute ischemic papillitis, partial CVR thrombosis, hypotonia (case 1), partial vitreous hemorrhage (case 4). No complications appeared in cases 2, 3, 5, and 6. No intraocular or orbital tumor recurrence or retinoblastoma metastases (follow-up range, 12-33 months) were observed. Sequential IAC and intravitreal melphalan for advanced retinoblastoma allowed to provide retinal and vitreous seed control.

Entities:  

Keywords:  Intra-arterial chemotherapy; Intravitreal chemotherapy; Retinoblastoma

Mesh:

Substances:

Year:  2015        PMID: 26416040     DOI: 10.1007/s10792-015-0129-8

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  12 in total

1.  Intravitreal chemotherapy for vitreous seeding in retinoblastoma: Recent advances and perspectives.

Authors:  Francis L Munier; Marie-Claire Gaillard; Aubin Balmer; Maja Beck-Popovic
Journal:  Saudi J Ophthalmol       Date:  2013-07

2.  Intravitreal melphalan for persistent or recurrent retinoblastoma vitreous seeds: preliminary results.

Authors:  Carol L Shields; Fairooz P Manjandavida; Sruthi Arepalli; Swathi Kaliki; Sara E Lally; Jerry A Shields
Journal:  JAMA Ophthalmol       Date:  2014-03       Impact factor: 7.389

3.  Selective ophthalmic arterial injection of melphalan for intraocular retinoblastoma: a 4-year review.

Authors:  Sherine Jue Ong; An-Ning Chao; Ho-Fai Wong; Kuan-Lyin Liou; Ling-Yuh Kao
Journal:  Jpn J Ophthalmol       Date:  2014-12-03       Impact factor: 2.447

4.  Profiling safety of intravitreal injections for retinoblastoma using an anti-reflux procedure and sterilisation of the needle track.

Authors:  Francis L Munier; Sameh Soliman; Alexandre P Moulin; Marie-Claire Gaillard; Aubin Balmer; Maja Beck-Popovic
Journal:  Br J Ophthalmol       Date:  2012-02-24       Impact factor: 4.638

5.  Intravitreal injection of melphalan in the treatment of retinoblastoma with vitreous cavity seeding.

Authors:  Ya-bin Sun; Peng Hui; Kharbuja Punyara; Ming-chao Bi; Song-he Li; Si-ying Teng; E Song
Journal:  Chin Med J (Engl)       Date:  2013       Impact factor: 2.628

6.  Superselective ophthalmic artery infusion of melphalan for intraocular retinoblastoma: preliminary results from 140 treatments.

Authors:  Carlo Venturi; Sandra Bracco; Alfonso Cerase; Samuele Cioni; Paolo Galluzzi; Paola Gennari; Ignazio M Vallone; Rebecca Tinturini; Cesare Vittori; Sonia De Francesco; Mauro Caini; Alfonso D'Ambrosio; Paolo Toti; Alessandra Renieri; Theodora Hadjistilianou
Journal:  Acta Ophthalmol       Date:  2012-01-23       Impact factor: 3.761

7.  Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications.

Authors:  Francis L Munier; Marie-Claire Gaillard; Aubin Balmer; Sameh Soliman; Gregory Podilsky; Alexandre P Moulin; Maja Beck-Popovic
Journal:  Br J Ophthalmol       Date:  2012-06-13       Impact factor: 4.638

8.  A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results.

Authors:  David H Abramson; Ira J Dunkel; Scott E Brodie; Jonathan W Kim; Y Pierre Gobin
Journal:  Ophthalmology       Date:  2008-03-14       Impact factor: 12.079

Review 9.  Ocular side effects following intravitreal injection therapy for retinoblastoma: a systematic review.

Authors:  Stephen J Smith; Brian D Smith; Brian G Mohney
Journal:  Br J Ophthalmol       Date:  2013-11-01       Impact factor: 4.638

10.  Classification and management of seeds in retinoblastoma. Ellsworth Lecture Ghent August 24th 2013.

Authors:  Francis L Munier
Journal:  Ophthalmic Genet       Date:  2014-10-16       Impact factor: 1.803

View more
  5 in total

1.  Retinal reattachment and ERG recovery after ophthalmic artery chemosurgery for advanced retinoblastoma in eyes with minimal baseline retinal function.

Authors:  Aliaa H Abdelhakim; Jasmine H Francis; Brian P Marr; Y Pierre Gobin; David H Abramson; Scott E Brodie
Journal:  Br J Ophthalmol       Date:  2016-08-18       Impact factor: 4.638

2.  Potential of Aqueous Humor as a Surrogate Tumor Biopsy for Retinoblastoma.

Authors:  Jesse L Berry; Liya Xu; A Linn Murphree; Subramanian Krishnan; Kevin Stachelek; Emily Zolfaghari; Kathleen McGovern; Thomas C Lee; Anders Carlsson; Peter Kuhn; Jonathan W Kim; David Cobrinik; James Hicks
Journal:  JAMA Ophthalmol       Date:  2017-11-01       Impact factor: 7.389

3.  Tumor Environment of Retinoblastoma, Intraocular Cancer.

Authors:  Dong Hyun Jo; Jin Hyoung Kim; Jeong Hun Kim
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

4.  The value of MRI in evaluating the efficacy and complications with the treatment of intra-arterial chemotherapy for retinoblastoma.

Authors:  Shuxian Chen; Xunda Ji; Ming Liu; Zhengrong Xia; Hui Zheng; Qiufeng Yin; He Wang; Yuhua Li
Journal:  Oncotarget       Date:  2017-06-13

5.  Functional genomics identifies new synergistic therapies for retinoblastoma.

Authors:  Arthur Aubry; Joel D Pearson; Katherine Huang; Izhar Livne-Bar; Mohammad Ahmad; Madhavan Jagadeesan; Vikas Khetan; Troy Ketela; Kevin R Brown; Tao Yu; Suying Lu; Jeffrey L Wrana; Jason Moffat; Rod Bremner
Journal:  Oncogene       Date:  2020-06-22       Impact factor: 9.867

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.